Tweets
First use of CAR-NK in myositis
Off-the-shelf CAR NK are more accessible, less onerous... unknown if equally effective
Early myositsi data; NKX019 was studied in 6 pts: 4 DM, 1 antisynthetase syndrome, 1 IMNM
Moderate-to-major TIS responses and no CRS or ICANS reported
Mike Putman @EBRheum ( View Tweet )
16 minutes 20 seconds ago
Real-world claims data study showed ANI improved immunologic, renal & hematologic parameters in SLE pts
Modest decr in UPCR (22%)
Most significant improvement seen in leucopenia (overall 55%, IS-naive 80%)
Improvement more prominent among IS-naive pts
@RheumNow #ACR26 Abs0921 https://t.co/ax8QeA1syu
sheila @RHEUMarampa ( View Tweet )
16 minutes 24 seconds ago
#ACR26 @RheumNow
Ab#0478
Baricitinib in 84 RA-ILD pts
Improved/stable dyspnea 83%, HRCT 68% at mean f/u 48 mos. DAS28-ESR from 4.3 to 2.8, median pred from 5 mg/d to 0 https://t.co/HTjUY7mHkV
Eric Dein @ericdeinmd ( View Tweet )
16 minutes 29 seconds ago
#ACR26 @RheumNow
Ab#0475 - AutoAb in ILD
48 pts analyzed
Anti-Sa Ab in 15%, Anti-CarP 25%
ILD in 8% pts, erosive RA in 15%
Sa - higher prev of ILD (43 v 2%), higher erosion but not signif
CarP not assoc w ILD, erosive disease (though previous associations have been reported)
Eric Dein @ericdeinmd ( View Tweet )
16 minutes 31 seconds ago
SUNSTAR (n=224): first head-to-head trial of 2 non-TNFi bDMARDs. SC tocilizumab did not demonstrate superiority to abatacept on week-26 CDAI change. A secondary composite response favoured tocilizumab (51% vs 36%); more infections reported. #0468 #ACR26 @Rheumnow https://t.co/TbRvR2qUZf
Mrinalini Dey @DrMiniDey ( View Tweet )
16 minutes 34 seconds ago
#ACR26 @RheumNow
Ab#0495
Leflunomide Duration and Dose - NOT associated with incident/progressive ILD
Longitudinal study of 184 RA patients
LEF associated with 4% lower risk of radiologic worsening, each gram of cumulative dose with 6.4% lower risk https://t.co/VeREpEQ5wc
Eric Dein @ericdeinmd ( View Tweet )
16 minutes 36 seconds ago
Which SIJ lesions drive an “MRI indicative of axSpA”?
-In SPARTAN CLASSIC (n=501, North America, <45y, undiagnosed back pain), erosion contributed most and was the only single lesion to hit ≥70% sens/≥90% spec.
-Fat lesion, backfill and ankylosis were highly specific but lacked https://t.co/olq564FhSz
Adela Castro @AdelaCastro222 ( View Tweet )
16 minutes 39 seconds ago
#ACR26 @RheumNow
Ab#0448 Addition of Nintedanib to Abatacept in RA-ILD
80 pts progressive ILD, 263 non-progressive. NNTE added to 6 prog, 13 non-prog
Non-prog- no signif results
In prog RA-ILD, ABA+NINTE showed stabilized FVC on f/u over 48 mo https://t.co/MPpzqT4ajr
Eric Dein @ericdeinmd ( View Tweet )
16 minutes 41 seconds ago
New IL-17 inhibitor on the block?
Post-hoc analysis of Izokibep (small, selective IL-17A inhibitor) shows significant improvement over placebo in high-threshold outcomes including ACR70 response by week 16
#Abst0360 @RheumNow #ACR26 https://t.co/5tXgxBXK3C
Brian Jaros, MD @Dr_Brian_MD ( View Tweet )
16 minutes 44 seconds ago
Obesity & biologic response in RA: good EULAR response at 6m was 49.4% with obesity vs 61.1% without. A 5-lipid signature tracked non-response in obesity group. A possible metabolic link between obesity and treatment response. Requires further validation. @Rheumnow #0099 #ACR26 https://t.co/8cz9jPY9hJ
Mrinalini Dey @DrMiniDey ( View Tweet )
16 minutes 50 seconds ago
TRIUMPH-4 • Conaghan et al.
TRIUMPH-4: Retatrutide improved knee OA pain and weight at 68 weeks. What is the biggest implication for OA care? @rheumnow #ACR2026 Abstract#0871
Audrey Gibson @Gibson_RheumPAC ( View Tweet )
16 minutes 52 seconds ago
#ACR26 @RheumNow
Ab#0244
Prospective study 106 pts - SSc <5 yr duration from 1st nonRP sx
Screening w HRCT, PFTs, auscultation
24% clinical ILD, 19% screening-detected ILD, 58% no ILD
33% pts w/o crackles had ILD on screening
Screen-detected ILD had higher serum MMP-7 to no ILD
Eric Dein @ericdeinmd ( View Tweet )
17 minutes 2 seconds ago
Jessen et al. Infection and ILD progression leading causes of death in RA-ILD. ILD was directly or indirectly involved in 2/3 of deaths. ILD-related deaths predominate with impaired FVC, infectious and CV deaths in those with preserved lung function @RheumNow #ACR26 Abstr#0503 https://t.co/VGdO7SsrJx
Richard Conway @RichardPAConway ( View Tweet )
17 minutes 7 seconds ago
#ACR26 @RheumNow
Ab#0221
Nintedanib in SSc-ILD, advanced progressing pts
36 pts, non-smokers, 39% dcSSc. Most background immunosuppr
Relative FVC decline >5% in 69%, >10% in 39%
AEs: 50% diarrhea, dose reduction in 64%, but permanent discontin in only 2 pts (6%)
33% escal to RTX https://t.co/kQnsPrbECB
Eric Dein @ericdeinmd ( View Tweet )
17 minutes 10 seconds ago
Abstract#0703 Multicenter observational study of RA-ILD pts tx with UPA (n=43). PFTs were stable for 24 month period, HRCT stable or improved in 90%. Remission or LDA by DAS-ESR in 60% of this pop.
DMARD to consider when RA-ILD is in play?
@ACR26 @RheumNow
Daric Mueller, PA-C @rheumPAC ( View Tweet )
17 minutes 13 seconds ago